title: Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
abstract: MicroRNAs play important roles in regulating the gene expression and life cycle of cancer cells. In particular, miR-21, an oncogenic miRNA is a major player involved in tumor initiation, progression, invasion and metastasis in several cancers, including triple negative breast cancer (TNBC). However, delivery of therapeutic miRNA or anti-miRNA specifically into cancer cells in vivo without collateral damage to healthy cells remains challenging. We report here the application of RNA nanotechnology for specific and efficient delivery of anti-miR-21 to block the growth of TNBC in orthotopic mouse models. The 15 nm therapeutic RNA nanoparticles contains the 58-nucleotide (nt) phi29 pRNA-3WJ as a core, a 8-nt sequence complementary to the seed region of miR-21, and a 39-nt epidermal growth factor receptor (EGFR) targeting aptamer for internalizing RNA nanoparticles into cancer cells via receptor mediated endocytosis. The RNase resistant and thermodynamically stable RNA nanoparticles remained intact after systemic injection into mice and strongly bound to tumors with little or no accumulation in healthy organs 8 h postinjection, and subsequently repressed tumor growth at low doses. The observed specific cancer targeting and tumor regression is a result of several key attributes of RNA nanoparticles: anionic charge which disallows nonspecific passage across negatively charged cell membrane; "active" targeting using RNA aptamers which increases the homing of RNA nanoparticles to cancer cells; nanoscale size and shape which avoids rapid renal clearance and engulfment by lung macrophages and liver Kupffer cells; favorable biodistribution profiles with little accumulation in healthy organs, which minimizes nonspecific side effects; and favorable pharmacokinetic profiles with extended in vivo half-life. The results demonstrate the clinical potentials of RNA nanotechnology based platform to deliver miRNA based therapeutics for cancer treatment.
authors.forename: Dan
authors.initials: D
authors.lastname: Shu
authors.forename: Hui
authors.initials: H
authors.lastname: Li
authors.forename: Yi
authors.initials: Y
authors.lastname: Shu
authors.forename: Gaofeng
authors.initials: G
authors.lastname: Xiong
authors.affiliation: OSU Comprehensive Cancer Center, The Ohio State University , Columbus, Ohio 43210, United States.
authors.forename: William E
authors.initials: WE
authors.lastname: Carson
authors.forename: Farzin
authors.initials: F
authors.lastname: Haque
authors.forename: Ren
authors.initials: R
authors.lastname: Xu
authors.forename: Peixuan
authors.initials: P
authors.lastname: Guo
mesh_terms: D000818:Animals; D052157:Aptamers, Nucleotide / Q000378:metabolism; D001483:Base Sequence; D001940:Breast / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006801:Humans; D051379:Mice; D035683:MicroRNAs / Q000037:antagonists & inhibitors* / Q000235:genetics; D008969:Molecular Sequence Data; D053758:Nanoparticles / Q000378:metabolism*; D036103:Nanotechnology; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000627:therapeutic use; D000067492:RNAi Therapeutics; D064726:Triple Negative Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*
chemical_list: D052157:Aptamers, Nucleotide; D004337:Drug Carriers; C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D034741:RNA, Small Interfering; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: EGFR RNA aptamer; RNA nanotechnology; miRNA; three-way junction; triple negative breast cancer